The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Open accessAbstract
Background The target-specific oral anticoagulant agents (TSOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in special situations and populations. Objectives This study’s objective is to systematically review and summarize current evidence regarding laboratory measurement of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban. Methods We searched PubMed and Web of Science for studies that reported a relationship between drug levels of dabigatran, rivaroxaban, and apixaban and coagulation assay results. Study quality was evaluated using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Results We identified 17 eligible studies for dabigatran, 15 for rivaroxaban, and 4 for apixaban. For dabigatran, a normal thrombin time excludes clinically relevant drug concentrations. The activated partial thromboplastin time (APTT) and prothrombin time (PT) are less sensitive and may be normal at trough drug levels. The dilute thrombin time (R2 0.92–0.99) and ecarin-based assays (R2 0.92–1.00) show excellent linearity across on-therapy drug concentrations and may be used for drug quantification. In terms of rivaroxaban and apixaban, anti-Xa activity is linear (R2 0.89–1.00) over a wide range of drug levels and may be used for drug quantification. Undetectable anti-Xa activity likely excludes clinically relevant drug concentrations. The PT is less sensitive (especially for apixaban); a normal PT may not exclude clinically relevant levels. The APTT demonstrates insufficient sensitivity and linearity for quantification. Conclusions Dabigatran, rivaroxaban, and apixaban exhibit variable effects on coagulation assays. Understanding these effects facilitates interpretation of test results in TSOAC-treated patients. More information on the relationship between drug levels and clinical outcomes is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Self-citationPerioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Weitz, J. I. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371007 · Cited by 1,533
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Self-citationStangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Self-citationStangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Martel, N., Lee, J., & Wells, P. S. (2005) · Blood · doi:10.1182/blood-2005-04-1546 · Cited by 875
Reilly, P. A., Lehr, T., Haertter, S., Connolly, S. J., Yusuf, S., Eikelboom, J. W., Ezekowitz, M. D., Nehmiz, G., Wang, S., & Wallentin, L. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.104 · Cited by 834
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Warkentin, T. E., Greinacher, A., Koster, A., & Lincoff, A. M. (2008) · Chest · doi:10.1378/chest.08-0677 · Cited by 816
Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
Raschke, R. A., Reilly, B. M., Guidry, J. R., Fontana, J. R., & Srinivas, S. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-9-199311010-00002 · Cited by 743
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P. C., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023143 · Cited by 612
PERZBORN, E., STRASSBURGER, J., WILMEN, A., POHLMANN, J., ROEHRIG, S., SCHLEMMER, K.-H., & STRAUB, A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01166.x · Cited by 590
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0176 · Cited by 449
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., Pedersen, K. E., Lionetti, D. A., Stangier, J., & Wallentin, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.034 · Cited by 419
Wang, Z., Frost, C., Shenker, A., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0328 · Cited by 356
Stangier, J., & Clemens, A. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609343004 · Cited by 337
Mueck, W., Lensing, A. W. A., Agnelli, G., Decousus, H., Prandoni, P., & Misselwitz, F. (2011) · Clinical Pharmacokinetics · doi:10.2165/11595320-000000000-00000 · Cited by 327
Robert, S., Chatelain, C., Douxfils, J., Mullier, F., Chatelain, B., & Dogné, J.-M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0804 · Cited by 325
Crowther, M. A., & Warkentin, T. E. (2008) · Blood · doi:10.1182/blood-2007-10-120543 · Cited by 314
Self-citationNutescu, E. A., Spinier, S. A., Wittkowsky, A., & Dager, W. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l194 · Cited by 289
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
HILLARP, A., BAGHAEI, F., FAGERBERG BLIXTER, I., GUSTAFSSON, K. M., STIGENDAL, L., STEN‐LINDER, M., STRANDBERG, K., & LINDAHL, T. L. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04098.x · Cited by 288
Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
Baghaei, F., Blixter, I. F., Gustafsson, K., Stigendal, L., Sten-Linder, M., Strandberg, K., Hillarp, A., Lindahl, T., & and from the expert group on coagulation of the External Quality Assurance in Laboratory Medicine in Sweden (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-06-0342 · Cited by 269
Upreti, V. V., Wang, J., Barrett, Y. C., Byon, W., Boyd, R. A., Pursley, J., LaCreta, F. P., & Frost, C. E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12114 · Cited by 269
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Stangier, J., & Feuring, M. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834f1b0c · Cited by 265
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man
Breckenridge, A., Orme, M., Wesseling, H., Lewis, R. J., & Gibbons, R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974154424 · Cited by 261
Baglin, T., Hillarp, A., Tripodi, A., Elalamy, I., Buller, H., & Ageno, W. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12149 · Cited by 256
Treatment of Venous Thromboembolism
Wells, P. S., Forgie, M. A., & Rodger, M. A. (2014) · JAMA · doi:10.1001/jama.2014.65 · Cited by 237
Contant, G., Spiro, T., Perzborn, E., Guinet, C., Gourmelin, Y., Flem, L., Rohde, G., Martinoli, J., Samama, M., & Laboratories, F. T. R. A.-F. X. C. A. F. T. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-06-0391 · Cited by 232
Hawes, E. M., Deal, A. M., Funk‐Adcock, D., Gosselin, R., Jeanneret, C., Cook, A. M., Taylor, J. M., Whinna, H. C., Winkler, A. M., & Moll, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12308 · Cited by 231
Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis
Lindh, J. D., Holm, L., Andersson, M. L., & Rane, A. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0584-5 · Cited by 218
Wang, D., Chen, H., Momary, K. M., Cavallari, L. H., Johnson, J. A., & Sadée, W. (2008) · Blood · doi:10.1182/blood-2008-03-144899 · Cited by 215
Anticoagulants and Their Reversal
Schulman, S., & Bijsterveld, N. R. (2007) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2006.08.002 · Cited by 212
Kubitza, D., Roth, A., Becka, M., Alatrach, A., Halabi, A., Hinrichsen, H., & Mueck, W. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12054 · Cited by 205
Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
Cavallari, L. H., Langaee, T. Y., Momary, K. M., Shapiro, N. L., Nutescu, E. A., Coty, W. A., Viana, M. A. G., Patel, S. R., & Johnson, J. A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.223 · Cited by 196
Bathala, M. S., Masumoto, H., Oguma, T., He, L., Lowrie, C., & Mendell, J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.046888 · Cited by 195
New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists
Scaglione, F. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0030-9 · Cited by 194
Heparin-induced thrombocytopenia in intensive care patients
Selleng, K., Warkentin, T. E., & Greinacher, A. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000259538.02375.a5 · Cited by 186
Laboratory assessment of new anticoagulants
Samama, M. M., & Guinet, C. (2011) · cclm · doi:10.1515/cclm.2011.134 · Cited by 174
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
LEVI, M., EERENBERG, E., & KAMPHUISEN, P. W. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04432.x · Cited by 170
Freyburger, G., Macouillard, G., Labrouche, S., & Sztark, F. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.01.001 · Cited by 157
Tamigniau, A., Châtelain, B., Chatelain, C., Wallemacq, P. E., Dogné, J., Mullier, F., & Douxfils, J. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0274 · Cited by 150
Becker, R. C., Yang, H., Barrett, Y., Mohan, P., Wang, J. J. J., Wallentin, L. C., & Alexander, J. H. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0591-8 · Cited by 148
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel
Caterina, R. D., Andreotti, F., Arnesen, H., Bachmann, F., Huber, K., Jespersen, J., Kristensen, S. D., Lip, G. Y. H., Morais, J., Rasmussen, L., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0228 · Cited by 144
Predictors of Bleeding During Heparin Therapy
Walker, A. M. (1980) · JAMA · doi:10.1001/jama.1980.03310110019020 · Cited by 142
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests
Asmis, L. M., Alberio, L., Angelillo‐Scherrer, A., Korte, W. C., Mendez, A., Reber, G., Seifert, B., Stricker, H. J., Tsakiris, D. A., & Wuillemin, W. A. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.06.031 · Cited by 140
Management of acquired haemophilia A
Collins, P. W. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04309.x · Cited by 121
Tripodi, A., Chantarangkul, V., GUINET, C., & Samama, M. M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04106.x · Cited by 119
Liesenfeld, K., Schäfer, H. G., Trocóniz, I. F., Tillmann, C., Eriksson, B. I., & Stangier, J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02667.x · Cited by 118
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays
Flaujac, C., Delavenne, X., Quenet, S., Horellou, M., Laporte, S., Siguret, V., Lecompte, T., & Gouin‐Thibault, I. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0470 · Cited by 116
Dager, W. E., Gosselin, R. C., Kitchen, S., & Dwyre, D. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r179 · Cited by 111
Coagulation assays and anticoagulant monitoring
Funk, D. M. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.460.3798662 · Cited by 111
Gross, P. L., & Weitz, J. I. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.98 · Cited by 108
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105
Rohde, G., Stratmann, G., Hesse, C., Herth, N., Schwers, S., Perzborn, E., Lindhoff‐Last, E., & Mani, H. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-12-0832 · Cited by 98
Helin, T., Pakkanen, A., Lassila, R., & Joutsi‐Korhonen, L. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.198788 · Cited by 88
Avecilla, S. T., Ferrell, C., Chandler, W. L., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpau7oqm0srpzq · Cited by 85
Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran
van Ryn, J., Baruch, L., & Clemens, A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.017 · Cited by 83
Butler, J., Malan, E., Chunilal, S. D., Tran, H., & Hapgood, G. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0301 · Cited by 83
Samama, M. M., Contant, G., Spiro, T. E., et al. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029611426282 · Cited by 83
Update on heparin: what do we need to know?
Weitz, D. S., & Weitz, J. I. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0411-6 · Cited by 77
Dinkelaar, J., Molenaar, P. J., Ninivaggi, M., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12236 · Cited by 72
Laboratory Measurements of the Oral Direct Factor Xa Inhibitor Edoxaban
MORISHIMA, Y., & Kamisato, C. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpq2njd3pxftug · Cited by 71
Prothrombin Time and Partial Thromboplastin Time Assay Considerations
Ng, V. L. (2009) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2009.05.002 · Cited by 68
Determination of Dabigatran in Human Plasma Samples
Harenberg, J., Christina, G., Marx, S., et al. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1300947 · Cited by 62
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests
Halbmayer, W., Weigel, G., Quehenberger, P., Tomasits, J., Haushofer, A. C., Aspoeck, G., Loacker, L., Schnapka-Köpf, M., Goebel, G., & Griesmacher, A. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2011-0888 · Cited by 62
Pharmacology of the new target-specific oral anticoagulants
Cabral, K. P. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0929-5 · Cited by 49
Molenaar, P. J., Dinkelaar, J., & Leyte, A. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0055 · Cited by 49
Novel anticoagulants and laboratory testing
Eby, C. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12065 · Cited by 48
A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors
Barrett, Y. C., Wang, Z., & Knabb, R. M. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612441859 · Cited by 39
New oral therapies for the prevention and treatment of venous thromboembolism
Hellwig, T. R., & Gulseth, M. P. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110601 · Cited by 8
Cited by
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Europace · doi:10.1093/europace/euw295 · Cited by 6,439
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Spahn, D. R., Bouillon, B., Cerny, V., Duranteau, J., Filipescu, D., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2347-3 · Cited by 1,269
Metadata
- Authors
- Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 64
- Issue
- 11
- Pages
- 1128-1139
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2001598988
- Cited by
- 449
- References
- 83
- FWCI
- 42.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.